Glenmark Pharmaceuticals announced a significant 76.1% increase in consolidated revenue for Q2 FY26, reaching ₹60,469 Mn. EBITDA surged by 292% to ₹23,596 Mn, with a margin of 39%. Profit After Tax (PAT) rose by 72.2% to ₹6,104 Mn, reflecting a PAT margin of 10.1%. The company highlighted strong performance in key markets and progress in its specialty and innovation businesses.
Financial Performance
Glenmark Pharmaceuticals reported consolidated revenue of ₹60,469 Mn for Q2 FY26, a significant increase from ₹34,338 Mn in the same quarter last year, marking a growth of 76.1%.
EBITDA for the quarter stood at ₹23,596 Mn, a 292% increase compared to ₹6,019 Mn in the corresponding period, resulting in an EBITDA margin of 39%.
Profit After Tax (PAT) reached ₹6,104 Mn, up by 72.2% year-over-year, with a PAT margin of 10.1%.
Regional Performance
Europe’s revenue increased by 8.5% year-over-year, reaching ₹7,460 Mn. North America’s business grew by 7.4%, excluding out-licensing income from the ISB 2001 deal.
Emerging Markets recorded revenue of ₹6,585 Mn, while India formulations revenue amounted to ₹1,650 Mn.
Business Updates
The company highlighted key milestones in its specialty and innovation businesses, including the global expansion of RYALTRIS® and the UK launch of WINLEVI®.
Glenmark launched TEVIMBRA® and BRUKINSA® in Q1 FY26, which have seen strong uptake.
Glenmark is preparing to launch RYALTRIS® in China by H1 FY27, while Organon, Glenmark’s partner in Thailand, plans to launch RYALTRIS® in Q4 FY26.
Glenmark has filed QiNHAYO™ Marketing Authorization Applications in 14 markets to date, with the first commercial launch expected in FY26.
IGI Pipeline Progress
IGI announced its partnership with AbbVie for ISB 2001 in July 2025. AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.
ISB 2301, a first-in-class NK cell-engager, had a Clinical Candidate selected in October 2025, and the program has entered the IND-enabling stage.
Source: BSE